p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
暂无分享,去创建一个
R. Rosell | A. Cardona | O. Arrieta | U. Malapelle | C. Rolfo | G. Recondo | L. Mas | A. Ruíz-Patiño | J. Garcia-Robledo | A. Russo | J. Rodríguez | J. Ávila | P. Archila | H. Carranza | C. Vargas | J. Otero | L. Zatarain-Barrón | C. Sotelo | Camila Ordoñez | L. Rojas | Maritza Bermúdez | T. Gámez | D. Mayorga | L. Corrales | Claudio Martín | S. Samtani | L. Ricaurte | F. Barrón | N. Santoyo | Maritza Bermudez | T. Gamez | C. Martin | July Rodríguez
[1] R. Reis,et al. Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer , 2021, JCO global oncology.
[2] Chuantao Zhang,et al. Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer , 2021, Scientific Reports.
[3] P. Jänne,et al. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation , 2020 .
[4] J. Desai,et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. , 2020, The New England journal of medicine.
[5] M. Meyerson,et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations , 2020, medRxiv.
[6] Edward S. Kim,et al. Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC). , 2020 .
[7] A. Azmi,et al. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? , 2020, Cancer treatment reviews.
[8] J. Desai,et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.
[9] W. Hwang,et al. Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. , 2019, JCO precision oncology.
[10] L. Moens,et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. , 2019, Lung cancer.
[11] R. Reis,et al. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations , 2019, Scientific Reports.
[12] M. Socorro,et al. Nuevos datos estadísticos genético-poblacionales para microsatélites en Colombia , 2019 .
[13] D. Balding,et al. Latin Americans show wide-spread Converso ancestry and imprint of local Native ancestry on physical appearance , 2018, Nature Communications.
[14] M. Schabath,et al. Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] M. Ladanyi,et al. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.
[16] J. Mazières,et al. Molecular biomarkers for lung adenocarcinoma , 2017, European Respiratory Journal.
[17] Jo-Anne Bright,et al. Population data on the expanded CODIS core STR loci for eleven populations of significance for forensic DNA analyses in the United States. , 2016, Forensic science international. Genetics.
[18] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[19] Matthew Meyerson,et al. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Shingo Matsumoto,et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.
[21] I. Louro,et al. New CODIS core loci allele frequencies for 96,400 Brazilian individuals. , 2014, Forensic science international. Genetics.
[22] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[23] Yi-long Wu,et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] M. Ladanyi,et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas , 2013, Cancer.
[25] Seungbok Lee,et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.
[26] Susanna M Cramb,et al. The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] S. Rodenhuis,et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.
[28] John M. Butler,et al. STRBase: a short tandem repeat DNA database for the human identity testing community , 2001, Nucleic Acids Res..